Rapid onset of proton-pump inhibitors to achieve a fast symptom is an unmet need in treating gastroesophageal reflux disease (GERD) but there was no report on the short-term clinical effects and timing to symptom relief comparing dexlansoprazole 60 mg to esomeprazole 40 mg. This pilot study aims to compare the one-week clinical effects of single doses of the two drugs in treating GERD patients.
A comparative study to different PPIs in pharmacokinetic change showing that after 12-24 hours post dose, mean percentage of time with pH \> 4 and average of mean pH were greater for dexlansoprazole than esomeprazole . However, the study did not report the clinical effect after tablets used. There was no report on the short-term clinical effects and timing to symptom relief of gastroesophageal reflux disease (GERD) between dexlansoprazole 60 mg and esomeprazole 40 mg. Therefore, we conducted a randomized controlled, open-label, study to compare the 7-day clinical effects of single doses of dexlansoprazole 60 mg and esomeprazole 40 mg in for GERD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
175
Esomeprazole 40mg qd
Dexlansoprazole 60mg qd
Rate of complete symptom resolution (CSR)
Evaluate the complete symptom resolution by questionnaire
Time frame: 1 week after finishing study drug
Rate of symptom relapse
Symptom relapse is defined as (a) two or more episodes of reflux symptoms per week that impair the quality of life
Time frame: 12 weeks after finishing study drug
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.